![](/img/cover-not-exists.png)
Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2
Monk, Bradley J., Poveda, Andrés, Vergote, Ignace, Raspagliesi, Francesco, Fujiwara, Keiichi, Bae, Duk-Soo, Oaknin, Ana, Ray-Coquard, Isabelle, Provencher, Diane M., Karlan, Beth Y., Lhommé, CatherineVolume:
143
Language:
english
Journal:
Gynecologic Oncology
DOI:
10.1016/j.ygyno.2016.07.112
Date:
October, 2016
File:
PDF, 1.09 MB
english, 2016